Market Feedback

Report
May 2022

© 2022. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 IPM Key Highlights
– May’2022
IPM Growth and Monthly Sale Trend
18,000 70

15,000 47.2 50

12,000 17.6 30
17.3 18.2 18.1 19.2 19.2
18.3 18.2
14.5 15.4
12.3
15.8 17.5 8.1
9,000 13.9 21.0 10
12.4
12.5 9.7 12.0
9.3 4.5
3.2
6,000 -6.3 -10
-9.4

3,000 -30
16,322.6

13,725.0

15,266.1

15,910.8

16,417.4

15,657.3

15,025.3

15,109.1

15,960.4

13,393.9

14,189.7

15,895.0

0 15,518.2 -50
May'21

May'22
July'21

Aug'21

Apr'22
Oct'21

Nov'21

Dec'21
June'21

Sept'21

Feb'22

Mar'22
Jan'22

Month Value'Cr Month growth MAT growth

• IPM was valued at Rs. 182,792 Cr for MAT May’22.

• IPM reported a degrowth of -6.3% for month of May’22 as
compared to the month of May’21.
• Corresponding to degrowth reported successively for the second
month, IPM MAT growth also declined to 8.1% for MAT May’22
as compared to 12.3% reported for MAT April’22.
• Trade segment contributes to 84.9% to IPM while Hospital
segment contributes to 9.1% and Doctor segment contributes to
6%. However, Trade segment has grown by 7.6%, hospital
segment has grown by 13.5% and doctor segment has grown the
lowest by 6.7% for MAT May’22.

Source: IQVIA TSA Dataset May’2022

1
Monthly Growth Trends
– May’2022
IPM May month growth trend as compared to
preceding April month
10.0%
8.5%
8.0%
6.0%
4.0% 2.7%
0.9% 1.5%
2.0% 1.0%
0.0%
-2.0%
-1.5% -2.0% -2.4%
-4.0% -2.7% -2.6%
-3.1%
-6.0% -4.7%
-5.6%
-8.0% -6.9%
-10.0% -8.6%
May'18 May'19 May'20 May'21 May'22
Acute Chronic Overall

Except May’18 and May’20, May overall sale has always been
lower than the previous April month sale. However, May’21 saw
the steepest decline in sale as shown in the above chart.

IPM May month growth trend as compared to

May month of previous year
95.0%
85.0%
75.0%
65.0% 60.8%
55.0% 49.3%
45.0%
31.9%
35.0%
25.0%
15.0% 11.7%13.0%12.2% 8.2% 10.7%9.1%
5.0% 0.8% 1.9%
-5.0%
-15.0% -7.6% -6.3%
-12.5% -10.7%
-25.0%
May'18 May'19Acute Chronic
May'20Overall May'21 May'22

May’21 exceptional high growth over May’20 could be one of

the main reasons for the IPM degrowth for May’22 as
compared to May’21 as shown in the above chart.

Source: IQVIA TSA Dataset May’2022

2
 IPM Acute/Chronic
Trends – May’2022
Acute vs. Chronic Trend
200,000 70%

180,000 60%

160,000 50%
14.2%
140,000 40%
10.8%

120,000 12.5% 30%

16.6% 7.3% 8.1%
7.3%
100,000 10.0% 8.5% 20%
8.6% 15.1%

80,000 6.7% 7.7% 7.9% 10%

5.7%

60,000 0%
124580.2

138071.6

148130.3

106531.3

169095.9

182791.7
114895.4
81263.7

43316.5

87545.0

50526.6

92541.7

55588.6

62564.5

67896.4

40,000 -10%

20,000 -20%
MAT May'18 MAT May'19 MAT May'20 MAT May'21 MAT May'22
ACUTE CHRONIC OVERALL Acute growth Chronic Growth Overall Growth

• Chronic segment has grown slightly faster @8.5% as compared

to acute segment, which has grown by 7.9% for MAT May’22.
• Anti-Infective, Gastrointestinal, Vitamins/Minerals/Nutrients are
the top 3 therapies of acute segment for MAT May’22. However,
for month of May’22, Gastrointestinal was ahead of Anti-
infective.
• Cardiac, Antidiabetic, Neuro/CNS are the top 3 therapies in
chronic segment for both MAT and month May’22. Highest
contribution to growth for this segment came from Cardiac
contributing 21.8% followed by Neuro/CNS @ 19.1% and
Respiratory @ 16.5% to the segment growth.

Source: IQVIA TSA Dataset May’2022

3
 Indian vs. MNC Trend
– May’2022
100,000 30%
Acute Segment-Indian vs. MNC
80,000 24%

87347.0
15.8%
18%
60,000 9.7%
12%
6.5% 12.3% 8.2%
40,000
70844.8

16700.2

75461.4

17080.3

19184.3

94548.2

20347.2
2.3% 6%
6.1%
20,000 0%
0.0%
0 -6%
MAT 05/2019'Cr MAT 05/2020'Cr MAT 05/2021'Cr MAT 05/2022'Cr

Indian MNC Indian Growth % MNC Growth %

• In the acute segment, Indian companies have grown by 8.2% while MNC
have grown by 6.1% for MAT May’22 as shown in the above chart.

Chronic Segment-Indian vs. MNC

60,000 17.6% 20%
50,000 16%
13.9%
50738.2

16.4%
40,000 10.7%
10.0% 12%
30,000
7.4% 7.0%
8%
20,000
40235.3

10291.3

44539.2

55802.9

12093.4
11049.4

11826.3

2.3%
10,000 4%

0 0%
MAT 05/2019'Cr MAT 05/2020'Cr MAT 05/2021'Cr MAT 05/2022'Cr
Indian MNC Indian Growth % MNC Growth %

• In the chronic segment, there is a big gap emerged in performance of

Indian companies and MNC from 2020. Indian companies have grown by
10% while MNC have grown by 2.3% for MAT May’22.

Overall-Indian vs. MNC

160,000 29%
24%
138085.3

120,000
15.1% 19%
12.1%
80,000 14%
8.0% 8.9%
120000.6

150351.1
111080.1

9%
26991.5

28129.7

31010.6

32440.7

40,000 10.2%
6.0% 4%
4.2% 4.6%
0 -1%
MAT 05/2019'Cr MAT 05/2020'Cr MAT 05/2021'Cr MAT 05/2022'Cr
Indian MNC Indian Growth % MNC Growth %

• At overall level, Indian companies grew by 8.9% while MNC grew by

4.6% for MAT May’22.

Source: IQVIA TSA Dataset May’2022

4
Top Companies in IPM
– May’2022

• La Renon, J.B Pharma, Corona Remedies, Ajanta Pharma

and IPCA Labs were the Top 5 fastest growing among the
Top 40 companies in IPM for MAT May’22.
• La Renon, Hegde &Hegde, Ajanta Pharma, Corona
Remedies and Intas Pharma were the Top 5 fastest growing
companies for the month of May’22 out of the Top 40
companies in IPM.
Movers and Shakers
In the month of May'22 (in comparison to Apr’22), among
the Top 40 companies
• Bharat Serum gained 14 ranks to reach 42nd position. 72
brands of TTK Healthcare were transferred to Bharat Serum
in May’22.
• Blue Cross gained 2 ranks to reach 31st position.
• DRL, Aristo, JB Pharma, Eris, Indoco, La Renon, Medley,
Win Medicare all gained 1 rank each to reach 10th, 11th, 23rd,
24th, 29th , 30th, 34th and 40th position, respectively.
As per MAT May'22 (in comparison to MAT Apr’22) among
the Top 40 companies
• Bharat Serum gained 21 ranks to reach 38th position.
• La Renon and Hegde & Hegde gained 2 ranks each to
reach 32nd and 39th position respectively.
• Torrent, Zydus, IPCA, P&G Health and Corona Remedies
gained 1 rank each to reach 8th, 11th, 18th ,31st and 37th
position, respectively.

Source: IQVIA TSA Dataset May’2022

5
Top Companies in IPM
– May’2022
RANKINGS MONTH May'22 MAT May'22
CORPORATIONS
Growth Growth
MAT MON Values In Cr MS % Values In Cr MS % EVOL
% %
IPM 15518.22 100 -6.28 182791.75 100 8.10 100
1 1 SUN* 1221.49 7.87 8.11 13935.40 7.62 11.86 103.5
2 2 ABBOTT* 993.65 6.40 5.71 11298.52 6.18 8.88 100.7
3 3 CIPLA 757.96 4.88 -17.72 9482.27 5.19 1.62 94.0
4 4 MANKIND 636.78 4.10 -10.80 7791.34 4.26 10.00 101.8
5 5 ALKEM* 626.38 4.04 -8.74 7139.14 3.91 13.41 104.9
6 6 LUPIN LIMITED 558.28 3.60 -4.04 6502.09 3.56 7.89 99.8
7 7 INTAS PHARMA* 536.45 3.46 15.76 6036.74 3.30 14.19 105.6
8 8 TORRENT PHARMA* 525.52 3.39 13.12 5816.97 3.18 9.51 101.3
9 9 MACLEODS PHARMA 486.86 3.14 -5.90 5815.60 3.18 13.60 105.1
10 10 DR REDDYS LABS 466.37 3.01 -10.58 5688.37 3.11 8.98 100.8
11 12 ZYDUS CADILA* 443.26 2.86 -8.40 5332.51 2.92 6.06 98.1
12 11 ARISTO PHARMA* 445.03 2.87 -13.42 5311.67 2.91 10.55 102.3
13 13 GLAXOSMITHKLINE* 368.20 2.37 -5.44 4750.02 2.60 6.80 98.8
14 16 GLENMARK PHARMA 303.01 1.95 -38.80 3878.12 2.12 -9.32 83.9
15 14 EMCURE* 326.99 2.11 -13.16 3831.21 2.10 7.21 99.2
16 15 USV 308.89 1.99 -2.69 3531.00 1.93 6.79 98.8
17 18 PFIZER* 283.08 1.82 -20.53 3450.48 1.89 0.16 92.7
18 17 IPCA LABS 284.54 1.83 11.71 3278.42 1.79 14.29 105.7
19 19 SANOFI* 262.70 1.69 -6.47 3114.36 1.70 3.59 95.8
20 20 MICRO LABS* 230.74 1.49 -11.29 2896.07 1.58 13.78 105.3
21 21 ALEMBIC 220.52 1.42 -12.73 2765.32 1.51 11.26 102.9
22 22 FDC 171.85 1.11 -1.79 1790.84 0.98 6.30 98.3
23 23 JB PHARMA* 156.10 1.01 10.97 1603.71 0.88 23.43 114.2
24 25 HIMALAYA DRUG 135.24 0.87 -7.54 1571.42 0.86 -3.15 89.6
25 24 ERIS LIFESCIENCES* 136.32 0.88 3.41 1551.19 0.85 7.35 99.3
26 26 CADILA PHARMA 127.60 0.82 -1.59 1430.46 0.78 5.70 97.8
27 28 FRANCO INDIAN 111.76 0.72 -28.69 1344.37 0.74 1.29 93.7
28 27 AJANTA PHARMA 117.56 0.76 24.76 1319.54 0.72 15.74 107.1
29 29 INDOCO* 95.43 0.61 -12.58 1211.75 0.66 8.58 100.4
30 31 BLUE CROSS 90.87 0.59 -13.95 1135.41 0.62 12.92 104.5
31 32 PROC.&GAMB.HEALTH 90.04 0.58 0.38 1070.16 0.59 6.60 98.6
32 30 LA RENON HEALTHCA. 94.63 0.61 37.11 1012.79 0.55 32.46 122.5
33 33 NOVARTIS INTL.* 89.53 0.58 8.00 995.33 0.54 -4.93 87.9
34 37 HETERO HEALTHCARE* 74.32 0.48 -60.28 966.10 0.53 -6.44 86.6
35 34 MEDLEY PHARMA 85.41 0.55 -1.59 940.48 0.51 5.37 97.5
36 36 SYSTOPIC 79.07 0.51 5.59 927.48 0.51 8.66 100.5
37 35 CORONA REMEDIES 83.33 0.54 18.35 923.42 0.51 18.60 109.7
38 42 BHARAT SERUM 63.26 0.41 -6.86 829.52 0.45 13.58 105.1
39 39 HEGDE & HEGDE 67.41 0.43 36.86 818.71 0.45 12.59 104.2
40 40 WIN MEDICARE 66.91 0.43 -19.20 818.70 0.45 -1.25 91.4

Source: IQVIA TSA Dataset May’2022

6
Top Brands in IPM
– May’2022
• Ryzodeg, Calpol, Udiliv, Dolo and Pan were
the top 5 fastest growing brands for MAT May’22
among the Top 40 brands in IPM.
• Manforce, Ryzodeg, Ultracet, Telma and Zerodol SP were
the Top 5 fastest growing brands for the month of May’22
among the Top 40 brands in IPM.
• Total number of SKUs with PTR changes in Feb’22
is 2209.
• Among the top 50 brands of the industry, PTR changes
reflected in SKUs of the following brands : Betadine,
Thyronorm, Pan, Dexorange, Azithral, Shelcal, Telma,
Aciloc, Ceftum, Manforce, Rosuvas, Rantac, Gluconorm-
G, A to Z NS & Cilacar.
Movers & Shakers TSA: Products
Among the Top 40 products as per May’22 Month (in
comparison to Apr’22 Month)
• Rantac gained 15 ranks to reach 29th position.
• Aciloc and Manforce gained 11 ranks each to reach 18th
and 28th position, respectively.
• Mikacin gained 6 ranks to reach 22nd position.
• Monocef gained 5 ranks to reach 6th position.

Among the Top 40 products as per May’22 MAT (in

comparison to Apr’22 MAT)
• Ultracet, Manforce and Rantac gained 4 ranks each to
reach 24th, 37th and 40th position respectively.
• Pan, Thyronorm, Ryzodeg, Duolin, Telma, Electral,
Shelcal and Levipil gained 2 ranks each to reach 11th, 9th,
29th ,19th, 23rd, 20th, 34th, and 27th position respectively.

Source: IQVIA TSA Dataset May’2022

7
Top Brands in IPM
– May’2022
RANKINGS MONTH May'22 MAT May'22
PRODUCTS MANU (Abbr.)
Values In Growth Values In Growth
MAT MON MS % MS % EVOL
Cr % Cr %
IPM 15518.22 100 -6.28 182791.75 100 8.10 100
1 1 MIXTARD ABT 71.56 0.46 1.52 842.40 0.46 0.68 93.14
2 2 GLYCOMET-GP USV 63.16 0.41 6.32 680.99 0.37 9.98 101.74
3 3 LANTUS S.A 51.98 0.33 -19.06 629.70 0.34 0.76 93.21
4 11 AUGMENTIN GSK 42.64 0.27 3.13 588.90 0.32 12.24 103.83
5 4 FORACORT CPL 47.22 0.30 -16.35 581.28 0.32 9.06 100.88
6 6 MONOCEF ATP 45.29 0.29 -26.03 556.30 0.30 13.85 105.32
7 8 LIV-52 HIM 43.65 0.28 -16.08 503.50 0.28 0.49 92.96
8 12 BETADINE WMC 38.75 0.25 -33.85 478.73 0.26 -9.88 83.37
9 7 THYRONORM ABT 44.55 0.29 15.01 476.47 0.26 11.28 102.94
10 15 CLAVAM A.K 36.90 0.24 -7.54 472.25 0.26 12.76 104.31
11 5 PAN A.K 45.37 0.29 5.98 469.12 0.26 20.27 111.26
12 26 CALPOL GSK 30.74 0.20 -46.57 453.76 0.25 27.40 117.85
13 13 NOVOMIX ABT 38.36 0.25 4.15 453.46 0.25 1.63 94.02
14 10 DEXORANGE F-I 43.02 0.28 -19.90 438.25 0.24 -7.89 85.21
15 24 JANUMET MSD 32.72 0.21 -10.68 420.71 0.23 -6.72 86.29
16 45 AZITHRAL AMB 24.74 0.16 -69.05 412.82 0.23 -4.52 88.32
17 14 PAN-D A.K 37.98 0.24 6.61 397.87 0.22 13.67 105.15
18 16 UDILIV SVY 35.57 0.23 12.50 396.74 0.22 23.76 114.49
19 32 DUOLIN CPL 28.60 0.18 -22.13 372.23 0.20 17.97 109.13
20 21 SHELCAL TNT 33.56 0.22 4.03 371.00 0.20 4.40 96.58
21 60 DOLO MRB 20.12 0.13 -54.49 366.41 0.20 21.86 112.73
22 25 ZERODOL-SP IPC 31.63 0.20 23.05 364.53 0.20 18.44 109.57
23 23 TELMA GMK 32.74 0.21 35.23 364.36 0.20 18.52 109.64
24 19 ULTRACET JAN 34.28 0.22 39.32 352.75 0.19 19.95 110.96
25 27 VOLINI RG. 30.56 0.20 3.52 352.17 0.19 5.51 97.6
26 55 PREVENAR-13 WYE 21.42 0.14 -13.10 345.04 0.19 -5.62 87.31
27 31 LEVIPIL SPI 29.15 0.19 5.82 340.11 0.19 6.06 98.12
28 30 BECOSULES PFZ 29.95 0.19 -38.71 339.11 0.19 -16.81 76.96
29 20 RYZODEG ABT 34.11 0.22 48.23 338.67 0.19 37.60 127.29
30 38 ZINCOVIT APX 25.94 0.17 -67.84 338.16 0.18 -24.41 69.92
31 17 DUPHASTON SVY 35.09 0.23 10.74 337.78 0.18 0.61 93.07
32 18 ACILOC CI6 34.80 0.22 3.45 325.89 0.18 -3.52 89.25
33 34 SEROFLO CPL 27.49 0.18 -0.39 314.46 0.17 6.00 98.05
34 9 ELECTRAL FC8 43.16 0.28 8.88 309.32 0.17 9.96 101.72
35 35 CEFTUM GSK 27.40 0.18 9.43 308.21 0.17 17.71 108.89
36 22 MIKACIN ATP 32.90 0.21 4.44 305.59 0.17 7.71 99.64
37 28 MANFORCE MA& 30.56 0.20 53.25 305.09 0.17 18.11 109.26
38 36 ROSUVAS RBY 26.68 0.17 9.69 300.94 0.16 17.19 108.41
39 43 ZIFI FC8 24.78 0.16 -4.82 294.47 0.16 13.64 105.13
40 29 RANTAC JBH 30.52 0.20 3.45 292.15 0.16 12.23 103.82

Source: IQVIA TSA Dataset May’2022

8
 Top Therapies in IPM –
May’2022
Month May'22 MAT May'22
Rank Rank Therapy Growth
Value 'Cr MS% Growth % Value 'Cr MS%
Month MAT %
IPM 15518.2 100.0% -6.3% 182791.7 100.0% 8.1%
1 1 CARDIAC 1938.0 12.5% -3.5% 22172.5 12.1% 5.5%
3 2 ANTI-INFECTIVES 1573.7 10.1% -28.0% 20547.0 11.2% 9.4%
2 3 GASTRO- INTESTINAL 1837.8 11.8% 11.5% 19265.7 10.5% 11.9%
4 4 ANTI DIABETIC 1477.4 9.5% 1.3% 16997.4 9.3% 5.4%
8 5 RESPIRATORY 1020.2 6.6% -30.6% 15452.3 8.5% 22.0%
5 6 VITAMINS/MINERALS/NUTRIENTS 1300.7 8.4% -14.1% 14771.7 8.1% 3.2%
6 7 PAIN / ANALGESICS 1233.7 7.9% 11.1% 14190.1 7.8% 14.1%
7 8 DERMA 1066.7 6.9% 1.6% 13096.6 7.2% 5.2%
9 9 NEURO / CNS 957.4 6.2% 14.8% 10904.4 6.0% 10.3%
10 10 GYNAEC. 858.9 5.5% 29.2% 9184.3 5.0% 15.1%
11 11 ANTINEOPLAST/IMMUNOMODULATOR 363.0 2.3% 23.4% 3552.4 1.9% 12.6%
12 12 OPHTHAL / OTOLOGICALS 317.0 2.0% 38.4% 3528.0 1.9% 19.9%
13 13 UROLOGY 312.1 2.0% 26.6% 3438.7 1.9% 15.2%
15 14 VACCINES 213.7 1.4% 1.5% 2907.9 1.6% 0.3%
14 15 HORMONES 233.0 1.5% -13.3% 2773.2 1.5% 5.0%
16 16 HEPATOPROTECTIVES 180.2 1.2% -0.6% 2058.0 1.1% 12.7%
17 17 BLOOD RELATED 146.2 0.9% 12.6% 1700.2 0.9% 10.2%
18 18 STOMATOLOGICALS 122.8 0.8% -9.9% 1340.1 0.7% 4.4%
19 19 ANTIVIRAL 73.8 0.5% -87.4% 1325.4 0.7% -63.5%
21 20 PARENTERAL 51.2 0.3% 2.6% 566.9 0.3% 23.8%

• Out of Top 20 therapies, Parenteral, Respiratory,

Opthal/Otological, Urology and Gynaec. were the Top 5 fastest
growing therapies in the same order at MAT level for May’22.
• Opthal/Otological, Gynaec., Urology,
Antineoplast/Immunomodulator, Neuro/CNS and Blood Related
were the Top 5 fastest growing therapies for the month of
May’22 in the same order.
• Opthal/Otological segment grew by 38.4% for the month of
May’22 as compared to month of April’22. Refresh Tears,
Combigan, Systane-Ultra, Genteal and Vigamox were the top 5
brands in this segment for the same period.
• Urology segment grew by 26.6% for the month of May’22 as
compared to April’22. Manforce, Urimax-D, Urimax, Megalis
and Cystone were the top 5 brands in this segment for the
same period.

Source: IQVIA TSA Dataset May’2022

9
Top New Brands
Launched in last 12
months-May’2022
Rank BRANDS COMPANY SUPERGROUP MAT MAY'22'Cr
1 DYDROGEST ZYDUS CADILA* GYNAEC. 36.6
2 POSAFORCE MANKIND DERMA 27.5
3 TOUJEO SANOFI* ANTI DIABETIC 27.4
4 RYBELSUS ABBOTT* ANTI DIABETIC 26.2
5 ZUVISTON EMCURE* GYNAEC. 24.2
6 LONOCART BHARAT SERUM CARDIAC 19.5
7 MOLNATRIS MYLAN PHARMA ANTIVIRAL 18.1
8 SGLTR-V MANKIND ANTI DIABETIC 17.0
9 DIVATRONE JAGSON PAL GYNAEC. 14.7
10 MOVFOR HETERO HEALTHCARE* ANTIVIRAL 14.7
11 TROMBOPAG NATCO PHARMA BLOOD RELATED 14.6
12 AMBILON-EM CELON LAB ANTI-INFECTIVES 12.8
13 DYDROSURE ALKEM* GYNAEC. 10.9
14 REMO-MV GLENMARK PHARMA ANTI DIABETIC 10.2
15 MYLAMIN GOLD MACLEODS PHARMA VITAMINS/MINERALS/NUTRIENTS 10.1
16 FARORIGHT SUN* ANTI-INFECTIVES 9.6
17 DROLUTE ERIS LIFESCIENCES* GYNAEC. 8.3
18 ACCU-CHEK ACTIVE ROCHE DIABETES OTHERS 7.7
19 CARITEC SUN* GYNAEC. 7.3
20 2 DG DR REDDYS LABS OTHERS 7.1

• Total 146 new products were launched in May’22. New brands

launched in last 12 month have clocked a sale of 1139.5 Cr as
compared to 1262.6 Cr reported last month.
• New products contributed 8.3% to IPM growth for MAT May’22.
By value, it contributed 0.6% to IPM.
• 62% of New products by value was launched in Acute segment
while 38% by value was launched in chronic segment in last 12
months ending May’22.
• Dydrogest (Zydus), Posaforce (Mankind), Zuviston (Emcure)
Molnatris (Mylan), and Divatron (Jagsonpal) were top selling
new brands launched in last 12 months in Acute segment.
• Toujeo (Sanofi), Rybelsus (Abbott*), Lonocart (Bharat Serum),
SGLTR-V (Mankind), Remo-MV (Glenmark) were top selling
new brands launched in last 12 months in chronic segment.

Source: IQVIA TSA Dataset May’2022

10
Performance of Top 30
Metros in IPM –May’2022
MAT May'21 MAT May'22 MAT May'21 MAT May'22

Rank Metro Values Growth Values Growth Rank Metro Values Growth Values Growth
Crores % Crores % Crores % Crores %

1 MUMBAI 7,469 15 % 7,756 4% 17 SURAT 855 17 % 935 9%

2 DELHI 6,603 4% 7,493 13 % 18 LUDHIANA 842 2% 913 8%
3 CALCUTTA 5,951 12 % 6,426 8% 19 KOCHI 808 -4 % 886 10 %
4 HYDERABAD 4,113 16 % 4,805 17 % 20 INDORE 787 32 % 838 6%
5 CHENNAI 3,324 10 % 3,757 13 % 21 VIJAYWADA 704 20 % 774 10 %
6 BANGALORE 3,295 5% 3,656 11 % 22 MADURAI 580 -1 % 711 23 %
7 LUCKNOW 2,098 16 % 2,294 9% 23 NASIK 731 35 % 703 -4 %
8 PUNE 2,101 10 % 2,138 2% 24 BHOPAL 627 29 % 664 6%
9 AHMEDABAD 1,802 27 % 1,898 5% 25 VADODARA 700 43 % 654 -7 %
10 JAIPUR 1,435 22 % 1,696 18 % 26 ALLAHABAD 564 13 % 612 9%
11 PATNA 1,415 18 % 1,578 12 % 27 JABALPUR 550 29 % 606 10 %
12 VARANASI 1,105 24 % 1,314 19 % 28 MEERUT 494 25 % 576 17 %
13 AGRA 1,005 25 % 1,213 21 % 29 VIZAG 517 16 % 530 3%
14 NAGPUR 1,073 23 % 1,085 1% 30 ASANSOL 319 19 % 353 10 %
15 COIMBATORE 950 27 % 1,008 6% Grand Total 53,732 14 % 58,849 10 %
16 KANPUR 914 18 % 978 7%

• Top 30 cities by pharma market size mentioned in the above

table grew faster @10% as compared to IPM growth of
8.1% for MAT May’22.
• Top 30 metros in India contributed to 32% to IPM Sales for
MAT May’22.
• Madurai, Agra, Varanasi, Jaipur and Hyderabad were the
fastest growing Pharma markets among the Top 30 metros
for MAT May’22.
• 18 out of 30 Top metros grew faster than IPM while
12 metros grew at par or slower than the IPM growth of
8.1% for MAT May’22.
• Out of the six base metros, Hyderabad recorded the fastest
growth of 16.8% followed by Delhi at 13.5%, Chennai at
13%, Bengaluru at 11%, Calcutta at 8% and Mumbai at
3.8% for MAT May’22.

Source: IQVIA TSA Dataset May’2022

11